Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

Yann Touchefeu,Rosine Guimbaud,Christophe Louvet,Laetitia Dahan,Emmanuelle Samalin,E. Barbier,K. Le Malicot,Romain Cohen,J. M. Gornet,Thomas Aparicio,S. Nguyen,A. Azzedine,Pierre-Luc Etienne,J-M. Phelip,Pascal Hammel,N. Chapelle,David Sefrioui,Laurent Mineur,Côme Lepage,O. Bouché

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

2019

Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2.

Keywords:

Medicine
Gastric Neoplasm
General surgery
Cancer
Oncology
Chemotherapy
Internal medicine
Adenocarcinoma
Irinotecan
Gastroenterology
FOLFIRI
Proportional hazards model
Capecitabine
Abdominal surgery
Epirubicin
Fluorouracil

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations